HighTower Advisors
DMII

HighTower Advisors’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

HighTower Advisors’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.12M Sell
714,614
-75,000
-9% -$747K 0.01% 1032
2025
Q4 		$7.82M Buy
+789,614
New +$7.81M 0.01% 967

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

HighTower Advisors's DMII Position: Q1 2026 in Review

HighTower Advisors reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 9.5% in Q1 2026, selling an estimated $747K and leaving 714,614 shares worth $7.12M. The position accounts for 0.01% of the portfolio, ranked #1032.

HighTower Advisors first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.82M in Q4 2025. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • HighTower Advisors held 714,614 shares of Drugs Made In America Acquisition II Corp worth $7.12M as of Q1 2026.
  • HighTower Advisors sold 75,000 Drugs Made In America Acquisition II Corp shares in Q1 2026, an estimated $747K.
  • Drugs Made In America Acquisition II Corp made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #1032 holding.
  • HighTower Advisors first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • HighTower Advisors's Drugs Made In America Acquisition II Corp position peaked at $7.82M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.